Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® ...

Regeneron Pharmaceuticals (NASDAQ:REGN) announced that the U.S. FDA has extended the target action dates for two regulatory ...

VivaVision Biotech welcomes renowned ophthalmologist Quan Dong Nguyen to its scientific advisory board with hopes of boosting ...

The NEW DAY study evaluating Iluvien for diabetic macular edema did not meet its primary endpoint, but showed favorable ...

Aflibercept 8mg late-breaking data presented at Retina Society in diabetic macular edema and wet age-related macular degeneration. News release. Regeneron Pharmaceuticals, Inc. November 4, 2022.

Aflibercept 8 mg is being jointly developed by Regeneron and Bayer AG. In the U.S., Regeneron maintains exclusive rights to EYLEA and aflibercept 8 mg. Bayer has licensed the exclusive marketing ...

An aflibercept biosimilar is “clinically equivalent” to the reference drug when used in the treatment of diabetic macular edema (DME), according to trial results published in JAMA Ophthalmology.

More eyes treated with aflibercept were successfully weaned off treatment at 1 year compared with eyes treated with bevacizumab, 43% vs. 15%, respectively (P < .0001).

The Protocol AC study analyzed visual acuity gains and cost if patients with diabetic macular edema started on bevacizumab, which costs less, and switched to aflibercept later, explained Jennifer ...

There were 35 eyes from 34 patients included in this study who were receiving aflibercept 2 mg; 73 eyes from 63 patients were receiving aflibercept 4 mg. Baseline PED height was thinner in the 4 ...